

CASE REPORT

A Case of Skin and Soft Tissue Infection Caused by *Mycobacterium abscessus*

Yong Hyun Kwon, M.D., Ga-Young Lee, M.D., Won-Serk Kim, M.D., Kea Jeung Kim, M.D.

Department of Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

Mycobacterium abscessus (*M. abscessus*) is an acid-fast bacillus that's classified as a pathogenic "rapid growing" nontuberculous mycobacteria. It is an uncommon cause of human disease, but it can cause skin and soft tissue infection after skin injury following inoculation, minor trauma and surgery. The single most important factor for determining the course and prognosis of a *M. abscessus* infection is the underlying immune status of the host. We report here on a 71-year-old female who presented with multiple painful erythematous cutaneous nodules on her left forearm. She had diabetes mellitus and had taken oral steroid by herself for two years because of her osteoarthritis. Histologically, granulomas and inflammatory cell infiltration were observed and *M. abscessus* was identified via the mycobacterial culture. We performed curettage and drainage, followed by 6 months of oral clarithromycin and the patient's disease completely healed. (**Ann Dermatol (Seoul) 21(1) 84~87, 2009**)

-Keywords-

Mycobacterium abscessus, Skin infection

INTRODUCTION

Mycobacterium abscessus (*M. abscessus*) is one of the rapidly growing mycobacterial species and it is found in soil, dust and water. *M. abscessus* was first described by Moore and Frerichs in 1953, and these organisms are

ubiquitous in the environment¹. It is an uncommon cause of human diseases, but it can cause skin and soft tissue infection after skin injury following inoculation, minor trauma or surgery^{1,2}. The single most important factor for determining the course and prognosis of a *M. abscessus* infection is the underlying immune status of the host³. Several cases of skin and soft tissue infection caused by *M. abscessus* have been reported in Korea⁴⁻⁸.

CASE REPORT

A 71-year-old woman visited our hospital with a week history of multiple painful erythematous swollen nodules and plaques on the left forearm (Fig. 1). She was a diabetes patient and had taken an injection of unknown material for managing the chronic pain of the affected arm. In addition, she had taken oral steroid by herself for about two years for treating her osteoarthritis.

The laboratory examinations to identify bacteria or fungus in the pus specimen from the patient revealed negative results. Acid fast bacilli (AFB) staining and polymerase



Fig. 1. Multiple erythematous swollen nodules on the left forearm.

Received February 20, 2008

Accepted for publication September 8, 2008

Reprint request to: Ga-Young Lee, M.D., Department of Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 108, Pyeong-dong, Jongno-gu, Seoul 100-634, Korea. Tel: 82-2-2001-2228, Fax: 82-2-2001-2236, E-mail: gygy.lee@samsung.com

chain reaction (PCR) analysis for mycobacteria (*M. tuberculosis* and mycobacterium other than tuberculosis) were also performed on the pus specimen and the results were negative.

Culture from the pus specimen on 3% Ogawa media showed yellowish colonies. The colonies were identified as *M. abscessus* by polymerase chain reaction-restriction fragment length polymorphism analysis (PCR-RFLP, PRA) with using the novel region of the rpo B gene obtained from the Korean Institute of Tuberculosis, Seoul, Korea




Fig. 2. Polymerase chain reaction-restriction fragment length polymorphism analysis (PCR-RFLP) shows 105 bp, 80 bp and 40 bp bands that were compatible with *Mycobacterium abscessus*.




Fig. 3. Note the polymorphonuclear microabscesses in the upper dermis and several epithelioid granulomas in the mid and deep dermis (H&E stain, $\times 40$).

(Fig. 2). The mycobacterial species showed resistance to isoniazid, rifampicin, streptomycin, ethambutol, kanamycin, capreomycin, prothionamide, cycloserine, pyrazinamide and ofloxacin.

The histological findings showed polymorphonuclear microabscesses and granulomatous inflammation in the dermis and subcutaneous fat tissue (Fig. 3, 4). No acid fast bacilli were observed by AFB staining. Gram staining and PAS staining were also negative. Culture and PCR analysis for mycobacteria were also performed on the tissue specimen and the results were negative.

Curettage and drainage, followed by 6 months of oral clarithromycin administration induced the complete healing of the lesions. After a 6 month remission period, similar skin lesions developed on the left forearm (Fig. 5). The patient had received acupuncture procedures on the left forearm to control pain of the arm. It was estimated that the skin lesions appeared 2 weeks after the initial




Fig. 4. The granuloma consisted of epithelioid cells and lymphoid cells (H&E stain, $\times 200$).



Fig. 5. After a 6 month remission period, a similar skin lesion developed on the left forearm.

acupuncture session. Any mycologic study from the pus specimen of new skin lesions revealed negative result. Skin biopsy showed granulomatous inflammation, but AFB staining, culture and PCR analysis from the tissue specimen showed negative results for *M. abscessus*. Considering that the clinical and pathologic features of the new infection were similar to those of the previous infection, we assumed that the lesions were caused by the recurrence or reinfection of *M. abscessus* and we administered oral clarithromycin for 3 months. The skin lesions showed improvement after a month of treatment.

DISCUSSION

The nomenclature of rapidly growing atypical mycobacteria has recently changed with the advent of biochemical techniques, which allow species to be more accurately identified. In the past they were simply identified as belonging to the '*M. fortuitum* complex'. Now, with using DNA homology studies, four separate species have been identified as *M. fortuitum*, *M. peregrinum*, *M. chelonae* and *M. abscessus*. Each of them is associated with different disease syndromes, and each of them has a distinct anti-microbial susceptibility pattern⁹.

M. abscessus was first described by Moore and Frerichs¹ in 1953, and this was isolated from a woman with chronic osteoarthritis. She developed gluteal abscesses that yielded the mycobacterium, and they termed the species 'abscessus'. Among the rapidly growing mycobacterial species, *M. abscessus* is known to be a major cause of skin infections. It is a cause of nosocomial infections, postinjection abscesses and wound infections following surgeries^{2,8,10}. Inman et al¹¹ reported an outbreak in 1969 amongst 12 patients who were being treated at an ENT clinic where all had received contaminated histamine injections. Galil et al¹² reported on a multistate outbreak of postinjection abscesses that were associated with the use of an unlicensed injectable product that was contaminated by mycobacterium. Multiple cutaneous abscesses have been reported in patients who are immunosuppressed, such as renal transplant recipients³. We believe the source of *M. abscessus* infection in our patient was the injection of unapproved medicine that she had taken on the arm. Her diabetes and chronic oral steroid medication might have played an important role in the manifestation and recurrence of her *M. abscessus* infection.

Cutaneous infections with rapidly growing mycobacteria can manifest in a variety of ways, including ulcerations, abscesses, draining sinuses or nodules^{2,8}. Histologically, rapidly growing mycobacteria are characterized by a dimorphic inflammatory response that consists of poly-

morphonuclear microabscesses in the dermis and subcutaneous tissues, along with epithelioid granulomas and giant cells¹³.

The diagnosis of cutaneous tuberculosis is usually difficult owing to false-negative cultures and negative direct-smear detection. The rapid detection and identification of *M. tuberculosis* or mycobacterium other than tuberculosis (MOTT) by PCR would provide a prompt differential diagnosis and guide proper management depending on the specific diagnosis. Yet there have been several reports on cases of false-negative results due to the absence of a multicopy gene in certain strains of mycobacteria, and false-positive results due to amplification from MOTT have been reported. *M. abscessus* and other mycobacterial species have recently been identified by employing more sensitive detection methods such as PCR-RFLP analysis^{6,8}.

The treatment of infection with rapidly growing mycobacteria depends on the extent of disease and the underlying immune status of the host³. *M. abscessus* is usually resistant to conventional anti-tuberculous drugs, and it is generally susceptible to parenteral therapy with amikacin, cefoxitin and imipenem, and to oral medication with clarithromycin^{2,3}. Because treatment usually extends for 3 to 6 months, oral clarithromycin is considered to be the first-line agent for localized *M. abscessus* infection⁸. It is not clear for how long treatment should be continued, but as with other mycobacterial infections, many authors feel that 6 months of treatment should be given, and especially for immunocompromised patients³. Our treatment started with 2nd generation cephalosporin and surgical drainage before the identification of the causative agent, but the lesion showed no improvement and then it became rather aggravated. Oral clarithromycin was administered after we identified *M. abscessus*, and the skin lesion showed improvement after a month of treatment.

Although rare, an atypical mycobacterial infection should be considered for the case of a local cutaneous infection that's resistant to antibiotic therapy, and especially if this is seen on an immunocompromised patient.

REFERENCES

1. Moore M, Frerichs JB. An unusual acid-fast infection of the knee with subcutaneous, abscess-like lesions of the gluteal region; report of a case with a study of the organism, *Mycobacterium abscessus*, n. sp. J Invest Dermatol 1953;20: 133-169.
2. Fitzgerald DA, Smith AG, Lees A, Yee L, Cooper N, Harris SC, et al. Cutaneous infection with *Mycobacterium abscessus*. Br J Dermatol 1995;132:800-804.
3. Morris-Jones R, Fletcher C, Morris-Jones S, Brown T, Hilton

- RM, Hay R. *Mycobacterium abscessus*: a cutaneous infection in a patient on renal replacement therapy. Clin Exp Dermatol 2001;26:415-418.
4. Lee SH, Kim KY, Hong SP, Kim MJ, Yang MH, Seou JT. A *Mycobacterium Chelonae* Subsp. *abscessus* wound infection after percutaneous endoscopic gastrostomy. Korean J Med 1997;53:842-846.
 5. Cho JH, Kim MY, Park YM, Kim HO. A case of cutaneous infection due to *Mycobacterium abscessus*. Korean J Dermatol 2004;42:512-515.
 6. Choi YL, Lee KJ, Lee DY, Lee ES. A case of skin infection caused by *Mycobacterium abscessus*. Korean J Dermatol 2005;43:852-855.
 7. Kim HS, Park HJ, Lee JY, Cho BK. Twelve cases of cutaneous infection by *Mycobacterium abscessus*: review on its treatment modality. Korean J Dermatol 2005;43:1603-1609.
 8. Ryu HJ, Kim WJ, Oh CH, Song HJ. Iatrogenic *Mycobacterium abscessus* infection associated with acupuncture: clinical manifestations and its treatment. Int J Dermatol 2005;44: 846-850.
 9. Wallace RJ Jr, Tanner D, Brennan PJ, Brown BA. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to *Mycobacterium chelonae*. Ann Intern Med 1993;119: 482-486.
 10. Brantley JS, Readinger AL, Morris ES. Cutaneous Infection with *Mycobacterium abscessus* in a child. Pediatr Dermatol 2006;23:128-131.
 11. Inman PM, Beck A, Brown AE, Stanford JL. Outbreak of injection abscesses due to *Mycobacterium abscessus*. Arch Dermatol 1969;100:141-147.
 12. Galil K, Miller LA, Yakus MA, Wallace RJ Jr, Mosley DG, England B, et al. Abscesses due to *mycobacterium abscessus* linked to injection of unapproved alternative medication. Emerg Infect Dis 1999;5:681-687.
 13. Rodriguez G, Ortegón M, Camargo D, Orozco LC. Iatrogenic *Mycobacterium abscessus* infection: histopathology of 71 patients. Br J Dermatol 1997;137:214-218.
-